Abstract
Drug-eluting stents confer no additional late cardiovascular risk in patients with stenting of large coronary arteries when compared with bare-metal stents according to the results of the 24-month Basel Stent Cost-effectiveness Trial-PROspective Evaluation Examination [BASKET-PROVE; ISRCTN72444640].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
